Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gordon James Freeman, Ph.D.

Co-Author

This page shows the publications co-authored by Gordon Freeman and Frank Hodi.
Connection Strength

1.535
  1. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 06; 5(6):480-492.
    View in: PubMed
    Score: 0.178
  2. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
    View in: PubMed
    Score: 0.160
  3. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
    View in: PubMed
    Score: 0.160
  4. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
    View in: PubMed
    Score: 0.145
  5. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364.
    View in: PubMed
    Score: 0.058
  6. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 06; 11(6):1524-1541.
    View in: PubMed
    Score: 0.058
  7. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
    View in: PubMed
    Score: 0.057
  8. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
    View in: PubMed
    Score: 0.055
  9. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.050
  10. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.046
  11. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res. 2017 11; 5(11):1046-1055.
    View in: PubMed
    Score: 0.046
  12. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430.
    View in: PubMed
    Score: 0.045
  13. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
    View in: PubMed
    Score: 0.042
  14. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 06 16; 1(9):e87415.
    View in: PubMed
    Score: 0.042
  15. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 08; 66(8):1463-1473.
    View in: PubMed
    Score: 0.041
  16. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
    View in: PubMed
    Score: 0.041
  17. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol. 2016 Apr; 40(4):443-53.
    View in: PubMed
    Score: 0.041
  18. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
    View in: PubMed
    Score: 0.041
  19. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008.
    View in: PubMed
    Score: 0.041
  20. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35.
    View in: PubMed
    Score: 0.040
  21. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
    View in: PubMed
    Score: 0.039
  22. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
    View in: PubMed
    Score: 0.038
  23. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
    View in: PubMed
    Score: 0.038
  24. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.